News

9 December 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to note the announcement that Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X3256) Under Fasting and Fed Conditions in Healthy Volunteers”.

13 November 19 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that at the General Meeting held earlier today in connection with the Company’s Placing, Subscription and Open Offer, details of which were announced on 24 October 2019, all resolutions put to shareholders were duly passed.

Thursday, 24 October 2019

Press Release Results of Placing

Successfully raises £7 million

 Advancing the next wave of out-licensing opportunities

24 October 2019 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to announce the completion of the Placing announced earlier today.

Advancing the next wave of out-licensing opportunities

24 October 2019 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces a proposed conditional Placing of Placing Shares with existing and new institutional investors and Subscription of Subscription Shares by certain Directors to raise a minimum of approximately £5.5 million in aggregate before expenses at the Issue Price of 15 pence per new Ordinary Share.

Tuesday, 01 October 2019

Press Release Business Update

1 October 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, today announces progress across a number of key programmes in line with its strategy.

27 September 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, is pleased to note Indivior PLC’s announcement that the National Institutes of Health (NIH) has granted Indivior's application entitled  "Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for the Treatment of Opioid Use Disorder" pursuant to Funding Opportunity Announcement RFA-DA-19-002 dedicated to the development of medications to prevent and treat opioid use disorder and overdose.

2 September 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today announces that Robin Carr, a renowned industry veteran who has worked at GSK and Astex, is to head up and form a C4XD Drug Discovery Advisory Network.

25 June 2019 – C4X Discovery Holdings plc (AIM: C4XD), a pioneering drug discovery company, today entered into a collaboration with PhoreMost, a UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets. The collaboration, focused initially in Parkinson’s Disease, will combine both company’s technology platforms.